Effectiveness of Olumiant vs b-tsDMARDs over 2 years.

0 SAR
Checkout

Overview

Watch Prof. Östörtake you through the key outcomes of the RA-BE-REAL study over 2 years.

This Class for

  • Physician
  • Resident / Fellow

What I will learn?

  • Prof. Östör, author of the RA-BE-REAL study, the main outcomes of the study are shared and supported by animations that bring the data to life. The video mostly covers the top-line outcomes of the publication, including discontinuation rates and remission/LDA rates. The main outcomes of the RA-BE REAL study are shared and supported by animations that make the data come to life and support the key outcomes as covered by Prof. Östör.





    Disclaimer

    This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
    (This information/content is intended to Health Care Providers only)

    For adverse events and safety reporting: email: saudi_pharmacovigilance@lilly.com
    24 /7 mobile : +966 567 868 843 working hours: +966 11 461 7800 , Ext: 1
    For Lilly product information: email: SAUDI_MEDINFOQUERIES@lilly.com
    For further information, please contact:
    Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: Saudi_Pharmacovigilance@lilly.com

    Please go to PDF Material for prescribing information


    PP-BA-SA-1188

Related Classes